Adherence to Protease Inhibitor Therapy and Outcomes in Patients with HIV Infection
Overview
Affiliations
Background: Combination antiretroviral therapy with protease inhibitors has transformed HIV infection from a terminal condition into one that is manageable. However, the complexity of regimens makes adherence to therapy difficult.
Objective: To assess the effects of different levels of adherence to therapy on virologic, immunologic, and clinical outcome; to determine modifiable conditions associated with suboptimal adherence; and to determine how well clinicians predict patient adherence.
Design: Prospective, observational study.
Setting: HIV clinics in a Veterans Affairs medical center and a university medical center.
Patients: 99 HIV-infected patients who were prescribed a protease inhibitor and who neither used a medication organizer nor received their medications in an observed setting (such as a jail or nursing home).
Measurements: Adherence was measured by using a microelectronic monitoring system. The adherence rate was calculated as the number of doses taken divided by the number prescribed. Patients were followed for a median of 6 months (range, 3 to 15 months).
Results: During the study period, 45,397 doses of protease inhibitor were monitored in 81 evaluable patients. Adherence was significantly associated with successful virologic outcome (P < 0.001) and increase in CD4 lymphocyte count (P = 0.006). Virologic failure was documented in 22% of patients with adherence of 95% or greater, 61% of those with 80% to 94.9% adherence, and 80% of those with less than 80% adherence. Patients with adherence of 95% or greater had fewer days in the hospital (2.6 days per 1000 days of follow-up) than those with less than 95% adherence (12.9 days per 1000 days of follow-up; P = 0.001). No opportunistic infections or deaths occurred in patients with 95% or greater adherence. Active psychiatric illness was an independent risk factor for adherence less than 95% (P = 0.04). Physicians predicted adherence incorrectly for 41% of patients, and clinic nurses predicted it incorrectly for 30% of patients.
Conclusions: Adherence to protease inhibitor therapy of 95% or greater optimized virologic outcome for patients with HIV infection. Diagnosis and treatment of psychiatric illness should be further investigated as a means to improve adherence to therapy.
Lopez C, Moreland A, Amaya S, Bisca E, Mujica C, Wilson T JMIR Form Res. 2025; 9:e64258.
PMID: 39819749 PMC: 11783029. DOI: 10.2196/64258.
Dabrowska A, Kazmierkiewicz R, Barabas-Lepak A, Biedulska M, Chylewska A J Phys Chem B. 2025; 129(3):911-929.
PMID: 39807672 PMC: 11770755. DOI: 10.1021/acs.jpcb.4c08136.
The effect of a combined mHealth and community health worker intervention on HIV self-management.
Dos Santos F, Batey D, Kay E, Jia H, Wood O, Abua J J Am Med Inform Assoc. 2025; 32(3):510-517.
PMID: 39798152 PMC: 11833470. DOI: 10.1093/jamia/ocae322.
Employment Status and HIV Viral Load in Chilean Adult Population: A Propensity Score Analysis.
Leiva-Escobar I, Cortes C, Lamadrid A AIDS Behav. 2025; .
PMID: 39779625 DOI: 10.1007/s10461-024-04600-y.
Malachias M, Kaiser S, Albuquerque D, Brandao A, Sposito A, Moura L Arq Bras Cardiol. 2024; 121(10):e20240469.
PMID: 39607399 PMC: 11634203. DOI: 10.36660/abc.20240469.